Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Kidney cancer

Therapy for metastatic RCC—questions remain

Nature Reviews Urology volume 6, pages 580–581 (2009)Cite this article

Tyrosine kinase inhibitors delay tumor progression and have a favorable adverse effect profile in patients with metastatic renal cell carcinoma; however, the impact of these treatments on objective clinical outcomes remains unknown. Updated results from two landmark phase III randomized trials now demonstrate the effect of sunitinib and sorafenib on survival.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Brugarolas, J. Renal-cell carcinoma—molecular pathways and therapies. N. Engl. J. Med. 356, 185–187 (2007).

    Article  CAS  PubMed  Google Scholar 

  2. Motzer, R. J. et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Escudier, B. et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312–3318 (2009).

    Article  CAS  PubMed  Google Scholar 

  4. Motzer, R. J. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).

    Article  CAS  PubMed  Google Scholar 

  5. Escudier, B. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125–134 (2007).

    Article  CAS  PubMed  Google Scholar 

  6. Sablin, M. P. et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J. Urol. 182, 29–34 (2009).

    Article  CAS  PubMed  Google Scholar 

  7. Motzer, R. J. et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372, 449–456 (2008).

    Article  CAS  PubMed  Google Scholar 

  8. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688–696 (1995).

    Article  CAS  PubMed  Google Scholar 

  9. Russo, P. & O'Brien, M. F. Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol. Clin. North Am. 35, 679–686 (2008).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Mayo Clinic, Rochester, MN, USA

    Rodney H. Breau & Bradley C. Leibovich

Authors
  1. Rodney H. Breau
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bradley C. Leibovich
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bradley C. Leibovich.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Breau, R., Leibovich, B. Therapy for metastatic RCC—questions remain. Nat Rev Urol 6, 580–581 (2009). https://doi.org/10.1038/nrurol.2009.210

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2009.210

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing